DYRK3 Knockout HAP1 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal population in which the dual-specificity kinase DYRK3 gene has been disrupted. This loss-of-function model enables investigation of DYRK3-dependent signaling without the confounding effects of residual protein expression. The polyclonal format ensures a heterogeneous genetic background, mimicking the natural variability encountered in cell populations while maintaining functional knockout across the majority of cells. By employing CRISPR/Cas9-mediated gene disruption, this product offers a robust tool for dissecting the mechanisms through which DYRK3 integrates nutrient and stress signals to control cell growth and survival, particularly in oncogenic contexts.
The host cell line, HAP1, is a near-haploid human adherent cell line derived from the KBM-7 chronic myeloid leukemia (CML) cell line. With its fibroblast-like morphology and a stable, simplified genome (primarily one copy of most chromosomes), HAP1 cells are uniquely suited for genetic knockout studies, as a single targeting event is sufficient to eliminate gene function. This haploid background reduces the complexity of interpreting knockout phenotypes and enhances the reliability of functional assays. HAP1 cells retain key signaling pathways relevant to leukemic biology, making them an ideal host for studying DYRK3??s oncogenic roles in CML and other malignancies.
DYRK3 is a dual-specificity kinase that positively regulates mechanistic target of rapamycin complex 1 (mTORC1) signaling by directly phosphorylating the inhibitory subunit PRAS40 (AKT1S1), thereby relieving inhibition on mTORC1 and promoting downstream anabolic processes. Under conditions of cellular stress, DYRK3 translocates to stress granules, where it phosphorylates scaffold proteins such as G3BP1 and TIA-1, driving stress granule disassembly and restoring translational activity. The active mTORC1 complex, comprising mTOR, Raptor, and mLST8, then phosphorylates key effectors including S6K and 4E-BP1 to stimulate protein synthesis and cell proliferation. Additionally, DYRK3 modulates autophagy by influencing ULK1 activity, linking mTORC1-driven growth signals to catabolic pathways. Upstream regulators include growth factor signaling and nutrient availability, which converge on DYRK3 through phosphorylation and subcellular localization changes.
In the HAP1 leukemic background, DYRK3 knockout disrupts the normal integration of stress and nutrient cues, allowing researchers to dissect how mTORC1 hyperactivation contributes to myeloid leukemogenesis. The near-haploid nature of HAP1 cells ensures efficient and stable knockout, making this polyclonal population an exceptional platform for high-throughput genetic screening and drug sensitivity profiling. By eliminating DYRK3, this model reveals the dependency of leukemic cells on mTORC1-mediated survival signals and stress granule dynamics, providing insights into potential therapeutic vulnerabilities. The interplay between DYRK3 and its interacting partners, such as 14-3-3 proteins and MDMX, can be systematically explored to validate novel targets in leukemia.
This polyclonal knockout product is broadly applicable to functional genomics and pharmaceutical research. Typical experimental workflows include Western blotting to assess phosphorylation of mTORC1 targets (e.g., p-S6K, p-4E-BP1), immunofluorescence to visualize stress granule dynamics using G3BP1 and TIA-1 markers, and autophagy flux assays to monitor ULK1-dependent processes. Cell proliferation assays and drug sensitivity screens are particularly effective for evaluating DYRK3 inhibitor candidates in a CML context. Co-immunoprecipitation experiments can map altered protein interactomes following DYRK3 disruption. For further information or technical support, please contact Ascent Research.
